Prostate doubling time may be valuable prognostic aid

Correct code selection depends on whether procedure is simple or complex.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.

In this patient population, erdafitinib reduced the risk of death by 36% versus physician's choice of chemotherapy.